

total share capital of the company)

# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office: Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat

Corp Office: 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058

Particulars	Quarter	Quarter	Quarter	Year	Year
	Ended	Ended	Ended	ended	Ended
	31-Mar-13	31-Dec-12	31-Mar-12	31-Mar-13	31-Mar-12
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1 (a). Net Income from Sales / Services	1,716.34	1,559.31	1,061.70	7,052.12	6,954.31
(b). Other Operating Income	10.75	0.68	0.19	26.57	0.77
Total Income	1,727.09	1,559.99	1,061.89	7,078.69	6,955.08
2. Expenditure					
a) (Increase)/Decrease in Stock in Trade/WIP	(326.99)	18.22	118.44	(160.09)	(588.77
b) Consumption of Raw Materials	1,905.14	1,562.56	780.11	6,687.82	6,497.48
c) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00
d) Employee Costs	27.25	23.39	16.23	85.40	79.88
e) Depreciation	6.12	5.59	4.11	24.15	19.28
f) Other Expenditure					
(i) Manufacturing Expenses	86.39	44.62	42.55	191.26	172.16
(ii) Administration Expenses	17.29	21.76	(7.08)		80.66
(iii) Selling & Distribution Expenses	17.12	25.48	26.77	52.01	77.20
g) Total	1,732.32	1,701.62	981.13	6,951.57	6,337.89
3. Profit from Operations before Other Income,	(5.23)	(141.63)	80.76	127.12	617.19
Interest and Exceptional Items	26.11	10.04	2.60	26.11	2421
4. Other Income	26.11	10.04	3.60 84.36	26.11 153.23	24.31 641.50
5. Profit before Interest and Exceptional items	20.88	(131.59)			
6. Interest	20.06	14.07	4.63	95.06	61.60 579.90
7. Profit after Interest but before Exceptional items	0.82	(145.66)	79.73	58.17 0.00	
8. Exceptional Items	0.00	0.00 (145.66)	0.00 79.73	58.17	0.00 579.90
Profit/(Loss) from ordinary activities before tax     Tax expense (incl deferred tax)	0.82	18.28	43.87	18.13	202.17
11 Net Profit/(Loss) from ordinary activities after tax	(0.13)	(163.94)	35.86	40.04	377.73
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	(0.13)	(163.94)	35.86	40.04	377.73
13. Net I font / (Loss) for the period	(0.13)	(103.74)	33.00	40.04	311.13
14. Paid-up Equity Share Capital	308.97	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	-		-	980.72	940.69
16. Earnings per share				700.72	710.03
a) Basic and diluted EPS before extraordinary	0.00	(5.31)	1.16	1.30	12.23
items for the period, year-to-date, previous year		(8.81)	1110	1.00	12.20
b) Basic and diluted EPS after extraordinary	0.00	(5.31)	1.16	1.30	12.23
items for the period, year-to-date, previous year		( )			
17. Public shareholding					
Number of shares	1,644,269	1,664,521	1,738,376	1,644,269	1,738,376
Percentage of shareholding	53.22	53.87	56.26	53.22	56.26
18. Promoters and promoter group shareholding**					
a) Pledged/ Encumbered					
Number of shares	0.00	0.00	0.00	0.00	0.00
Percentage of shares (as a % of the	0.00	0.00	0.00	0.00	0.00
total shareholding of promoter and					
promoter group)					
Percentage of shares (as a % of the	0.00	0.00	0.00	0.00	0.00
total share capital of the company)					
b) Non-encumbered					
Number of shares	1,445,431	1,425,179	1,351,324	1,445,431	1,351,324
Percentage of shares (as a % of the	100.00	100.00	100.00	100.00	100.00
total shareholding of promoter and					
promoter group)					
Percentage of shares (as a % of the	46.78	46.13	43.74	46.78	43.74
total above comital of the comments)					



## **Samrat Pharmachem Limited**

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Standalone Statement of Assets and Liabilities Particulars	Year to	Year to
Tartediary	date ended	date ended
	31-Mar-2013	31-Mar-2012
	(Audited)	(Audited)
EQUITY AND LIABILITIES SHAPEHOLDERS FUNDS.		
SHAREHOLDERS' FUNDS: (a) Capital	308.97	308.97
(b) Reserves and Surplus	980.72	940.69
(c) Money Received Against Share Warrants	0.00	0.00
Sub total- Shareholders' Fund	1,289.69	1,249.66
SHARE APPLICATION MONEY PENDING ALLOTMENT	0.00	0.00
NON CURRENT LA DILITIES		
NON - CURRENT LIABILITIES	100.00	122.02
(a) Long-Term Borrowings (b) Deferred Tax Liabilities (Net)	100.88 29.91	132.02 25.02
(c) Other Long-Term Liabilities	0.00	0.00
(d) Long-Term Provisions	0.00	0.00
Sub total- Non Current Liabilities	130.79	157.04
CURRENT LIABILITIES	130.77	137.04
(a) Short-Term Borrowings	329.56	210.06
(b) Trade Payables	1,596.90	1,385.53
(c) Other Current Liabilities	43.45	3.81
(d) Short-Term Provisions	0.00	145.46
Sub total- Current Liabilities	1,969.91	1,744.86
Total - Equity and Liabilities	3,390.39	3,151.56
ASSETS		
NON-CURRENT ASSETS		
(a) Fixed Assets	728.97	639.15
(b) Non-Current Investment	0.00	0.00
(c) Deferred Tax Assets (Net)	0.00	0.00
(d) Long-Term Loans And Advances	13.37	10.27
(e) Other Non-Current Assets	17.07	13.76
Sub total- Non Current Assets	759.41	663.18
CURRENT ASSETS		
(a) Current Investment	0.00	0.00
(b) Inventories	972.97	736.73
(c) Trade Receivables	1,176.77	1,050.13
(d) Cash And Cash Equivalents	256.25	444.87
(e) Short-term loans and advances	3.00	2.16
(f) Other current assets	221.99	254.49
Sub total- Current Assets	2,630.98	2,488.38
Total - Assets	3,390.39	3,151.56



## Samrat Pharmachem Limited

### Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

#### **Notes:**

- 1. The above results were reviewed by the Audit Committee of the Board of Directors.
- The above results have been taken on record by the Board of Directors at it Meeting held on Thursday, 30 May 2013 at the Corporate Office of the Company.
- 3. The above figures are after accounting for a net foreign exchange loss of Rs.134.93 lakhs during the year.
- 4. The figures of the quarter ended 31st March 2013 and 31st March 2012 are the balancing figures between the audited figures in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
- 5. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 31 March, 2013:

Opening Balance as on 31/Dec/2012 0
Received during the quarter 0
Disposed of during the quarter 0
Closing Balance as on 31/Mar/2013 0

6. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

By order of the Board of Directors For Samrat Pharmachem Limited

Place: Mumbai Lalit Mehta
Date: 30 May 2013 Managing Director